11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 25.11.2025 Expectation: 1200 pips
NVIDIA’s quarterly report may send its shares down to $170
Today at 12:11 PM 21
Period: 26.11.2025 Expectation: 1050 pips
USDCAD hovers near lower boundary of ascending channel
Today at 11:02 AM 23
Period: 30.06.2026 Expectation: 15000 pips
Selling USDJPY from upper limit of descending triangle
Today at 09:42 AM 20
Period: 30.04.2026 Expectation: 21000 pips
Buying Bitcoin from support at $86,000
Today at 08:37 AM 14
Period: 26.11.2025 Expectation: 600 pips
EURUSD undergoes technical rebound amid dollar strength
Today at 07:37 AM 27
Period: 25.11.2025 Expectation: 4500 pips
Buying Bitcoin when consolidating above $89,000
Yesterday at 11:56 AM 33
Go to forecasts